...
首页> 外文期刊>Journal of glaucoma >A novel approach to suprachoroidal drainage for the surgical treatment of intractable glaucoma.
【24h】

A novel approach to suprachoroidal drainage for the surgical treatment of intractable glaucoma.

机译:脉络膜上引流的新方法用于顽固性青光眼的外科治疗。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: In glaucoma surgery, scarring of the artificial fistula is the limiting factor for long-term control of intraocular pressure (IOP). Several devices and surgical techniques have been developed for artificial aqueous humor drainage in intractable glaucoma. The authors describe a novel surgical technique that uses a silicone tube as a shunt for aqueous flow from the anterior chamber to the suprachoroidal space. PATIENTS AND METHODS: Thirty-one eyes of 31 patients with uncontrollable refractory glaucoma were included in this prospective consecutive case-control study. Each eye had undergone an average of 3.5+/-1.9 previous interventions for glaucoma. The baseline IOP was 44.25+/-8.7 mm Hg despite maximum therapy. As in trabeculectomy, a limbus-based scleral flap was prepared. The suprachoroidal space was accessed via a deep posterior scleral flap. The silicone tube was inserted as an intrascleral connection from the anterior chamber to the suprachoroidal space. Cyclodialysis was avoided by this surgical approach. Success was defined as a lowering of IOP to below 21 mm Hg without the need for further medication or intervention. RESULTS: The mean functional shunt survival was 55.9+/-45.6 weeks. IOP was reduced to 12.9+/-5.2 mm Hg in 70% of all eyes after 30 weeks postoperatively. After 52 weeks, 60% of the eyes could be classified as representing success, and 76 weeks after surgery, 40% of the eyes still showed controlled IOP. In none of the eyes were severe postoperative hypotony or suprachoroidal bleeding observed. No localized or general inflammation or infection was seen in connection with the silicon tube. Two patients needed anterior chamber lavage because of bleeding. In 2 patients the tube had to be removed because of corneal endothelial contact. Shunt failure of the tube was caused in some cases by connective tissue formation at the posterior lumen of the tube. CONCLUSION: This novel surgical approach and the placement of the silicone tube described here have several advantages. Its intrascleral course minimizes the risk of conjunctival erosion and associated infections. No cyclodialysis is performed. Connection to the suprachoroidal space exploits the resorptive capability of the choroid. It guarantees drainage but also provides a natural counterpressure, avoiding severe postoperative hypotony. The suprachoroidal shunt presented here achieves good follow-up results in terms of IOP control. No serious complications have been observed. This new method promises to be an effective surgical technique and presents a new therapeutic option in intractable glaucoma. Fibroblast reaction obstructing the posterior lumen, seemed to be the only factor limiting drainage. Further studies and experiments will be needed to elucidate the exact physiologic mechanisms underlying the draining, the capacity and duration of the draining effect, and the histologic background of suprachoroidal scarring.
机译:目的:在青光眼手术中,人造瘘管的瘢痕形成是长期控制眼内压(IOP)的限制因素。已经开发出几种用于难治性青光眼的人工房水引流的装置和手术技术。作者描述了一种新颖的外科手术技术,该技术使用硅胶管作为分流器,以使水从前房流向脉络膜上腔。患者与方法:这项前瞻性连续病例对照研究纳入了31例无法控制的难治性青光眼患者的31只眼。每只眼睛以前接受过平均3.5 +/- 1.9的青光眼干预。尽管进行了最大程度的治疗,但基线IOP仍为44.25 +/- 8.7 mm Hg。如在小梁切除术中一样,准备了一个基于角膜缘的巩膜瓣。脉络膜上腔通过深后巩膜瓣进入。硅胶管从前房到脉络膜上腔插入为巩膜内连接。通过这种手术方法避免了血液透析。成功的定义是无需进一步药物治疗或干预即可将IOP降至21 mm Hg以下。结果:平均功能性分流生存时间为55.9 +/- 45.6周。术后30周,在70%的所有眼睛中,IOP降至12.9 +/- 5.2 mm Hg。 52周后,可以将60%的眼睛归为代表成功,而在手术76周后,仍有40%的眼睛表现出受控的IOP。术后均未观察到严重的低渗或脉络膜上腔出血。硅管未见局部或全身发炎或感染。两名患者因出血而需要洗前房。在2例患者中,由于角膜内皮接触,不得不将其取下。在某些情况下,管的分流失败是由于在管的后腔形成结缔组织引起的。结论:这种新颖的手术方法和此处介绍的硅胶管的放置有几个优点。其巩膜内病程将结膜糜烂和相关感染的风险降至最低。不执行环透析。与脉络膜上腔的连接利用了脉络膜的吸收能力。它既保证了引流,又提供了自然的反压,避免了术后严重的肌张力低下。本文介绍的脉络膜上分流在眼压控制方面取得了良好的随访结果。没有观察到严重的并发症。这种新方法有望成为一种有效的外科手术技术,并为顽固性青光眼提供了新的治疗选择。成纤维细胞反应阻塞后腔,似乎是限制引流的唯一因素。需要进一步的研究和实验来阐明引流的确切生理机制,引流作用的能力和持续时间,以及脉络膜上瘢痕形成的组织学背景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号